Learn why Zack’s has increased its price target on BSEM to $23.25!

Get in Early on a MedTech Company with $23.25 Price Target! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [Unsubscribe]( [Growing revenues have led to another price target increase for BioStem Technologies Inc. (OTC: BSEM) at Zack’s!]( Two massive multi-billion-dollar markets for its regenerative therapies position[BioStem Technologies Inc. (OTC: BSEM)]( how many kinds of companies are in it. It’s all about finding emerging players like BSEM who have successfully navigated the regulatory process (a real barrier to entry) and show real growth. Zack’s Small Cap Research recently increased its price target to $23.25, recognizing the company’s value after it reported Q1 financial results. Zack’s Small Cap Research has stated, “We reiterate our belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future.” The company states its mission is “to discover, develop and produce the most effective regenerative medicine products in the world,” and Zack’s believes that the company is well on its way to achieving that goal—providing to investors what the firm believes is an opportunity to invest in a company that is both providing a vital service to the human population and providing economic value to shareholders when doing so. 2023 was a pivotal year for BSEM which has established a solid foundation for the company's future expansion, which now includes a potential uplisting to a senior stock exchange! [See how BioStem Technologies, Inc. (OTC: BSEM) is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds!]( --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for BioStem Technologies, Inc. (BSEM) from Sideways Frequency. StockEarnings.com and Daily Options Signals, Inc receives a fixed fee of $3,000 for two Dedicated Email Sends. Other than the compensation received for this advertisement sent to subscribers, Daily Options Signals and its principals are not affiliated with either BioStem Technologies, Inc. (BSEM) or Sideways Frequency. Daily Options Signals and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Daily Options Signals nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Daily Options Signals to buy or sell any security. Daily Options Signals has not evaluated the accuracy of any claims made in this advertisement. Daily Options Signals recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies, Inc. (BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies, Inc. (BSEM). Your privacy is very important to us. If you no longer wish to receive email from DailyOptionsSignals.com, please click [Unsubscribe]( . StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com